Fulcrum Therapeutics (FULC) Gains from Investment Securities (2019 - 2025)
Fulcrum Therapeutics (FULC) reported Gains from Investment Securities of -$200000.0 for Q4 2025, up 75.4% year-over-year from -$114025.2 in Q4 2024, and down 116.42% quarter-over-quarter from $1.2 million in Q3 2025.
Fulcrum Therapeutics (FULC) Gains from Investment Securities (2019 - 2025) Analysis & Trends
Fulcrum Therapeutics (FULC) has 7 years of Gains from Investment Securities data on file, last reported at -$200000.0 in Q4 2025.
- Gains from Investment Securities for Q4 2025 came in at -$200000.0, up 75.4% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.0 million (down 42.08% YoY), and the FY2025 annual result was $11.6 million, up 24.49% from the prior year.
- Gains from Investment Securities eased to -$200000.0 in Q4 2025 per FULC's latest filing, from $1.2 million in the prior quarter.
- Over five years, Gains from Investment Securities peaked at $12.3 million in Q1 2024 and troughed at -$813000.0 in Q4 2024.
- A 5-year average of $2.6 million and a median of $500000.0 in 2021 frame the typical range for Gains from Investment Securities.
- The sharpest annual moves came in 2021 and 2025: Gains from Investment Securities slumped 96.44% in 2021, then soared 11982.31% in 2025.
- A 5-year view of Gains from Investment Securities shows it stood at $500000.0 in 2021, then surged by 1085.81% to $5.9 million in 2022, then sank by 70.73% to $1.7 million in 2023, then tumbled by 146.84% to -$813000.0 in 2024, then surged by 75.4% to -$200000.0 in 2025.
- Business Quant data shows FULC's Gains from Investment Securities at -$200000.0 in Q4 2025, $1.2 million in Q3 2025, and $12.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - |
| 10 | Fulcrum Therapeutics | 267.90 Mn | 267.90 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -200,000.00 |
| Dec 31, 2025 | -200,000.00 |
| Sep 30, 2025 | 1.22 Mn |
| Sep 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 12.08 Mn |
| Jun 30, 2025 | 12.08 Mn |
| Dec 31, 2024 | -813,000.00 |
| Dec 31, 2024 | -813,000.00 |
| Sep 30, 2024 | 2.86 Mn |
| Sep 30, 2024 | 2.86 Mn |
| Jun 30, 2024 | 100,000.00 |
| Jun 30, 2024 | 100,000.00 |
| Mar 31, 2024 | 12.29 Mn |
| Mar 31, 2024 | 12.29 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Mar 31, 2023 | 1.74 Mn |
| Sep 30, 2022 | 5.93 Mn |
| Sep 30, 2022 | 5.93 Mn |
| Jun 30, 2022 | 2.25 Mn |
| Jun 30, 2022 | 2.25 Mn |